BioNTech SE
NASDAQ:BNTX

Watchlist Manager
BioNTech SE Logo
BioNTech SE
NASDAQ:BNTX
Watchlist
Price: 95.81 USD -4.43% Market Closed
Market Cap: 23B USD

Relative Value

The Relative Value of one BNTX stock under the Base Case scenario is 30.82 USD. Compared to the current market price of 95.81 USD, BioNTech SE is Overvalued by 68%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BNTX Relative Value
Base Case
30.82 USD
Overvaluation 68%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
25
vs Industry
48
Median 3Y
3.3
Median 5Y
3.3
Industry
6.9
Forward
9.7
vs History
vs Industry
1
Median 3Y
3.3
Median 5Y
3.4
Industry
23
Forward
-15.7
vs History
6
vs Industry
2
Median 3Y
4
Median 5Y
3.6
Industry
19.7
vs History
vs Industry
11
Median 3Y
4.1
Median 5Y
3.2
Industry
22.8
vs History
84
vs Industry
57
Median 3Y
1.3
Median 5Y
1.9
Industry
2.6
vs History
39
vs Industry
66
Median 3Y
1.3
Median 5Y
1.3
Industry
7.4
Forward
1.7
vs History
39
vs Industry
67
Median 3Y
1.5
Median 5Y
1.6
Industry
9.3
vs History
vs Industry
12
Median 3Y
1.4
Median 5Y
1.7
Industry
4.1
Forward
-2.3
vs History
vs Industry
11
Median 3Y
1.4
Median 5Y
1.4
Industry
4.1
Forward
-2
vs History
15
vs Industry
6
Median 3Y
1.6
Median 5Y
1.2
Industry
4.9
vs History
vs Industry
17
Median 3Y
1.3
Median 5Y
1
Industry
3.6
vs History
85
vs Industry
56
Median 3Y
1.6
Median 5Y
2.3
Industry
4.7

Multiples Across Competitors

BNTX Competitors Multiples
BioNTech SE Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
BioNTech SE
NASDAQ:BNTX
23B USD 7.3 -30.4 -4.2 -3.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 873 287.2 -165 747.6 -201 270.4 -198 973.7
US
Abbvie Inc
NYSE:ABBV
328.7B USD 5.7 79.1 15.1 22.3
US
Amgen Inc
NASDAQ:AMGN
155B USD 4.5 26.1 14.1 23.3
US
Gilead Sciences Inc
NASDAQ:GILD
137B USD 4.8 23 10 13.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.6B USD 10.2 -114.9 24.4 25.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 020.1 -515.5 -561.3 -546.4
AU
CSL Ltd
ASX:CSL
119.6B AUD 5.1 28 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
53B USD 3.8 11.8 10.4 11.7
US
Seagen Inc
F:SGT
39.3B EUR 19.5 -59.7 -64.3 -58
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
39.7B USD 16.9 -147.2 -658.7 -330.1
P/S Multiple
Revenue Growth P/S to Growth
DE
BioNTech SE
NASDAQ:BNTX
Average P/S: 3 170 489.6
7.3
-6%
N/A
FR
Pharnext SCA
OTC:PNEXF
34 873 287.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
2 020.1
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
3.8
5%
0.8
US
S
Seagen Inc
F:SGT
19.5
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.9
29%
0.6
P/E Multiple
Earnings Growth PEG
DE
BioNTech SE
NASDAQ:BNTX
Average P/E: 33.6
Negative Multiple: -30.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 747.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
79.1
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -114.9 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -515.5 N/A N/A
AU
CSL Ltd
ASX:CSL
28
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
7%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -147.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DE
BioNTech SE
NASDAQ:BNTX
Average EV/EBITDA: 15.2
Negative Multiple: -4.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 270.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.1
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.1
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.3 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.4
11%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -658.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DE
BioNTech SE
NASDAQ:BNTX
Average EV/EBIT: 19.7
Negative Multiple: -3.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 973.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.3
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -546.4 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.7
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -330.1 N/A N/A